High Burden and Phenotype‐Specific Variability of Pain Polypharmacy in Early Autoimmune Rheumatic Diseases: A 14‐Year Analysis

BACKGROUND: Pain drives disability and medication use in autoimmune rheumatic diseases (ARDs), even when inflammation is controlled. The extent of pain-related polypharmacy across ARDs and chronic overlapping pain conditions (COPCs) remains poorly characterized. We aimed to quantify first-year pain medication burden following ARD diagnosis and examine variations by disease, COPC status, and time. METHODS: Using the Merative MarketScan Commercial Claims database, we identified adults newly diagnosed with rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, psoriatic arthritis, Sjögren's disease, or systemic sclerosis (2008-2021). We analyzed pain-related medications across 10 pharmacologic categories during the first year postdiagnosis. Polypharmacy measures included counts of distinct pain medications, medication categories, ≥ 5 and ≥ 10 medication thresholds, and the Medication Quantification Scale. FINDINGS: Among 149 742 adults with newly diagnosed ARDs, 57.6% had at least one COPC. During the first year after diagnosis, patients filled a mean of 9.0 distinct pain medications and 47.9% met criteria for ≥ 5 medications; 30.5% met criteria for ≥ 10 medications. Ankylosing spondylitis demonstrated the highest medication burden (mean 11.6 medications; 57.5% with ≥ 5 medications; 37.9% with ≥ 10 medications). Patients with fibromyalgia had consistently higher medication burden across ARDs and were the only COPC group in whom prescribing increased from 2015 onward. Overall medication burden rose from 2008 to 2014-2015 and declined thereafter; however, absolute levels remained high. INTERPRETATION: Pain-related polypharmacy is common early after ARD diagnosis and varies substantially by disease and pain phenotype. Despite modest declines from 2015 onward, medication burden remains high, underscoring the need for phenotype-informed, nonpharmacologic, and deprescribing strategies in rheumatology.

Authors

Institutions

Publication Details

Journal
Pharmacoepidemiology and Drug Safety
Published
2026-10-14
DOI
https://doi.org/10.1002/pds.70501
Primary Topic
Pharmaceutical Practices and Patient Outcomes
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

High Burden and Phenotype‐Specific Variability of Pain Polypharmacy in Early Autoimmune Rheumatic Diseases: A 14‐Year Analysis

Macarius M. Donneyong, Michael H. Weisman, D Lu, James Cragun et al.
Pharmacoepidemiology and Drug Safety
Pharmaceutical Practices and Patient Outcomes
article

High Burden and Phenotype‐Specific Variability of Pain Polypharmacy in Early Autoimmune Rheumatic Diseases: A 14‐Year Analysis

Macarius M. Donneyong, Michael H. Weisman, D Lu, James Cragun, Kristen May Cunanan, Matthew Baker, Titilola Falasinnu, Anushka Soni, Md. Belal Hossain, Lauren Vuong
article en

Abstract

BACKGROUND: Pain drives disability and medication use in autoimmune rheumatic diseases (ARDs), even when inflammation is controlled. The extent of pain-related polypharmacy across ARDs and chronic overlapping pain conditions (COPCs) remains poorly characterized. We aimed to quantify first-year pain medication burden following ARD diagnosis and examine variations by disease, COPC status, and time. METHODS: Using the Merative MarketScan Commercial Claims database, we identified adults newly diagnosed with rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, psoriatic arthritis, Sjögren's disease, or systemic sclerosis (2008-2021). We analyzed pain-related medications across 10 pharmacologic categories during the first year postdiagnosis. Polypharmacy measures included counts of distinct pain medications, medication categories, ≥ 5 and ≥ 10 medication thresholds, and the Medication Quantification Scale. FINDINGS: Among 149 742 adults with newly diagnosed ARDs, 57.6% had at least one COPC. During the first year after diagnosis, patients filled a mean of 9.0 distinct pain medications and 47.9% met criteria for ≥ 5 medications; 30.5% met criteria for ≥ 10 medications. Ankylosing spondylitis demonstrated the highest medication burden (mean 11.6 medications; 57.5% with ≥ 5 medications; 37.9% with ≥ 10 medications). Patients with fibromyalgia had consistently higher medication burden across ARDs and were the only COPC group in whom prescribing increased from 2015 onward. Overall medication burden rose from 2008 to 2014-2015 and declined thereafter; however, absolute levels remained high. INTERPRETATION: Pain-related polypharmacy is common early after ARD diagnosis and varies substantially by disease and pain phenotype. Despite modest declines from 2015 onward, medication burden remains high, underscoring the need for phenotype-informed, nonpharmacologic, and deprescribing strategies in rheumatology.

Pharmacoepidemiology and Drug SafetyVol. 35(11)
Jacksonville College (US), Stanford Medicine (US), The Ohio State University (US), Stanford University (US)
Lupus Research Alliance, National Institute of Arthritis and Musculoskeletal and Skin Diseases
Good health and well-being
Openalex Percentile: Top 15%
Pharmaceutical Practices and Patient Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.